Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abhijit Pal

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
JCO Oncology Practice|September 7, 2023
Improving Access to Cancer Clinical Trials for Patients From Culturally and Linguistically Diverse Backgrounds in Australia: A Survey of Clinical and Research ProfessionalsAbhijit Pal, Ben Smith, Christie Allan, et al.
Clinical Genitourinary Cancer|August 4, 2022
Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate CancerUdit Nindra, Jun Hee Hong, Bavanthi Balakrishnar, et al.
Critical Reviews in Oncology/Hematology|January 22, 2021
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspectiveJulia Lai-Kwon, Crescens Tiu, Abhijit Pal, et al.
Nature Reviews. Clinical Oncology|March 25, 2021
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug developmentAbhijit Pal, Rajiv Shinde, Manuel Selvi Miralles, et al.
Carbohydrate Polymers|March 17, 2020
An elastic semi IPN polymer hybrid for enhanced adsorption of heavy metalsAbhijit Pal, Tamalika Das, Srijoni Sengupta, et al.
Journal of Immigrant and Minority Health|March 4, 2010
Vitamin D deficiency in refugee children from conflict zonesMohamud Sheikh, Shu Wang, Abhijit Pal, et al.
Cancer Medicine|August 1, 2025
Improving Ethnic Diversity in Cancer Trials Through Healthcare Interpreter TrainingSuzanne J Grant, Mayra Ouriques, Abhijit Pal, et al.
Psycho-Oncology|October 15, 2021
Assessing cognitive toxicity in early phase trials - What are we missing?Sarah E Stapleton, Anne-Sophie Darlington, Anna Minchom, et al.
Clinical Genitourinary Cancer|May 29, 2024
Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell TumorsRoger Liang, Diana Adams, Felicia Roncolato, et al.
Oncology|January 17, 2024
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical OncologistsUdit Nindra, Victoria Bray, Deme Karikios, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
JCO Oncology Practice|September 7, 2023
Improving Access to Cancer Clinical Trials for Patients From Culturally and Linguistically Diverse Backgrounds in Australia: A Survey of Clinical and Research ProfessionalsAbhijit Pal, Ben Smith, Christie Allan, et al.
Clinical Genitourinary Cancer|August 4, 2022
Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate CancerUdit Nindra, Jun Hee Hong, Bavanthi Balakrishnar, et al.
Critical Reviews in Oncology/Hematology|January 22, 2021
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspectiveJulia Lai-Kwon, Crescens Tiu, Abhijit Pal, et al.
Nature Reviews. Clinical Oncology|March 25, 2021
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug developmentAbhijit Pal, Rajiv Shinde, Manuel Selvi Miralles, et al.
Carbohydrate Polymers|March 17, 2020
An elastic semi IPN polymer hybrid for enhanced adsorption of heavy metalsAbhijit Pal, Tamalika Das, Srijoni Sengupta, et al.
Journal of Immigrant and Minority Health|March 4, 2010
Vitamin D deficiency in refugee children from conflict zonesMohamud Sheikh, Shu Wang, Abhijit Pal, et al.
Cancer Medicine|August 1, 2025
Improving Ethnic Diversity in Cancer Trials Through Healthcare Interpreter TrainingSuzanne J Grant, Mayra Ouriques, Abhijit Pal, et al.
Psycho-Oncology|October 15, 2021
Assessing cognitive toxicity in early phase trials - What are we missing?Sarah E Stapleton, Anne-Sophie Darlington, Anna Minchom, et al.
Clinical Genitourinary Cancer|May 29, 2024
Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell TumorsRoger Liang, Diana Adams, Felicia Roncolato, et al.
Oncology|January 17, 2024
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical OncologistsUdit Nindra, Victoria Bray, Deme Karikios, et al.
Pageof 5